In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...

Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...

* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET ...

Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

Figure: Solution structure of human MANF protein. PDB ID: 2KVD [7]. Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived neurotrophic factor (MANF) form an evolutionary ...

Herantis Pharma`s clinical study with CDNF in Parkinson`s disease authorized in Sweden Herantis Pharma Plc Company release 23 March 2017 at 12:30 pm The Medicines Agency of Sweden, MPA, has authorized ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

With a horrific mortality and recovery rate, intracerebral hemorrhage (ICH) is a devastating disease with poor long-term outcomes for those who do manage to survive it. And studies show that for ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...